What is the efficacy of idarucizumab (Praxbind) as an anticoagulation reversal agent for deep venous thrombosis (DVT)?

Updated: Jun 05, 2019
  • Author: Kaushal (Kevin) Patel, MD; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
  • Print

Idarucizumab is a humanized antibody fragment directed against dabigatran. This agent has been shown to completely reverse the anticoagulant effect of dabigatran within minutes; on October 16, 2015, it was approved by the FDA as an antidote for dabigatran. [148, 149, 150, 151]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!